The Board of Directors is ultimately responsible for the strategy and organisation, as well as the management of operations. The Board appoints the CEO, who is responsible for managing the day-to-day operations in accordance with guidelines from the Board.
The Annexin Board of Directors is comprised of a number of experienced individuals that together have a wide range of expertise within various aspects of pharmaceutical development, such as investments, acquisitions, licensing, product launch, and marketing.
Jan Nilsson
Chairman of the Board since 2024
Born: 1949 Nationality: Swedish
Education and professional experience: Jan Nilsson holds a M.Sc. from the University of Gothenburg and an MBA from Uppsala University. Jan has long and broad experience from both large pharmaceutical companies and biotech firms. He has been active in several different therapeutic areas in the pharmaceutical industry and has, in addition to participating in the product development process, also had key roles in the launch, sales and marketing of established international brands. Jan also has solid management background, having served as CEO in both public and private companies.
Other assignments: Jan is currently Chairman of the Board of CCRM Nordic AB (svb) and a member of the Board of Directors of CarryGenes Therapeutics AB and Urbicum Ledningskonsult AB.
Independent in relation to the Company and its management as well as in relation to the Company’s major shareholders. Shareholding in the Company: No shares. 200 000 warrants serie 2024/2027.
Mikael Lönn
Member of the Board since 2024
Born: 1949 Nationality: Swedish
Education and professional experience: Mikael is a M.Sc. and physician with extensive experience as a business leader and entrepreneur, primarily in the healthcare sector. He has extensive experience in financial investments and solid experience from advising and actively engaging with the board of directors in a number of start-up and growth companies as well as experience from large county council and municipal-owned organizations.
Other assignments: Today, Mikael has board assignments in several companies, including Chairman of the Board of Wingspan Company Culture AB and Thioredoxin Systems AB as well as Board member of Genovis AB (publ), Oxlantic Medical AB, Redeye AB/Redhold AB, Vasa Angels 1 AB, Mikael Lönn AB, Professional Corporate Governance in Sweden AB, Professional Corporate Governance PÄAB ll, and Collabodoc AB.
Independent: Mikael has been a shareholder in Annexin Pharmaceuticals since 2016. Mikael is not independent in relation to the company, its management or major shareholders. Mikael Lönn is the largest shareholder with 26.0 percent ownership in Annexin Pharmaceuticals AB.
Shareholding in the Company: 138 405 749 shares
Carl-Fredrik Lindner
Member of the Board since 2017
Born: 1976 Nationality: Swedish
Education and professional experience: Carl-Fredrik Lindner has a Master of Computer Science from KTH Royal Institute of Technology, Stockholm, Sweden. He has a background in Corporate Finance and worked with a Venture Capital fund, investing in Life Science. Other assignments: Investment Manager at Lionpeak AB.
Independent in relation to the Company and its management as well as in relation to the Company’s major shareholders. Shareholding in the Company: 1 040 005 shares
Mikael von Euler
Member of the Board since 2023
Born: 1953 Nationality: Swedish
Education and professional experience: Mikael von Euler is a licensed physician with a PhD from Karolinska Institutet. Von Euler is a trained oncologist with more than 30 years of experience from the pharmaceutical industry. He was previously Senior Vice President and CMO of Aprea Therapeutics, CMO of KDevOncology, Akinion, Axelar and Oncos Therapeutics (now Targovax). He has held several senior positions within the global organization of large pharmaceutical companies, including Cluster Head of Roche/Genentech, Vice President of GlaxoSmithKline and Global Product Director of AstraZeneca. Other assignments: Board member of Dicot AB (publ) and M Von Euler Consulting AB.
Independent in relation to the Company and its management as well as in relation to the Company’s major shareholders. Shareholding in the Company: 240 000 shares
Management
Management
The management team of Annexin Pharmaceuticals has a long experience within the area of research and development of pharmaceutical products; from preclinical stage to market authorisation application, including mergers, acquisitions and licensing.
Anders Haegerstrand
Chief Executive Officer
Born: 1961 Nationality: Swedish Position: Board member 2018-2020, Chief Executive Officer since 2019
Education and professional experience: Anders Haegerstrand has extensive R&D experience including drug discovery and development as manager at Karolinska Institutet, Astra Pain Control AB and AstraZeneca LLC and within biotech. From year 2000, Anders was CEO and CSO for NeuroNova AB, a leading company in applied stem cell research that brought to protein molecules into Phase I/II clinical studies. The company was later acquired by a listed company, Newron Pharmaceuticals S.p.A., at which Anders was a management team member between 2013 and 2016.
Shareholding in the Company: 1 834 863 shares, 300 000 warrants serie 2022/2025 and 5 000 000 warrants serie 2024/2027.
Anna Frostegård
Chief Scientific and Medical Officer
Born: 1973 Nationality: Swedish Position: Co-founder and inventor since 2014. Chief Scientific and Medical Officer since 2016.
Education and professional experience: Anna Frostegård, MD, PhD, Licensed Physician, is a globally educated Licensed Physician who earned her Doctor of Medicine degree summa cum laude and earned her Doctor of Philosophy degree in Experimental Medicine from Karolinska Institutet. She has served as an Assistant Professor at the Unit of Immunology and Chronic Disease and has more than 10 years’ experience in translating academic discoveries into the development of biological drugs. Anna is one of the inventors and co-founder of Annexin Pharmaceuticals and is an expert in Annexin A5, vascular inflammation and cardiovascular diseases.
Shareholdings in the Company: 8 791 546 shares indirectly through Medirista AB as well as 150 000 warrants serie 2022/2025 and 5 000 000 warrants serie 2024/2027.
Susan Suchdev
Chief Operating Officer
Born: 1972 Nationality: Swedish Position: Chief Operating Officer since 2018
Education and professional experience: Susan Suchdev has a M.Sc. from Karolinska Institutet in Stockholm. Earlier she had the position as COO at Klaria Pharma and has previously had a long career with management roles in clinical development projects, including Pfizer, TFS Trial Form Support and Nestlé Health Science.
Shareholding in the Company: 288 126 shares, 150 000 warrants serie 2022/2025 and 900 000 warrants serie 2024/2027. 168 000 shares via related parties.
Susanne Andersson
Chief Financial Officer
Born: 1971 Nationality: Swedish Position: Chief Financial Officer since 2023
Education and professional experience: Susanne Andersson holds a Bachelor of Business Administration from College of Charleston, S.C. USA. She has long-standing experience as CFO with investor relations responsibility from a number of international listed companies in various industries, including Sedana Medical, Pricer, ChromoGenics and Nordic Mines as well as financial management positions, including investor relations at Ericsson within the telecom industry.
Shareholding in the Company: No shares. 300 000 warrants serie 2024/2027.
Therapeutic Area Heads
Therapeutic Area Heads
Mario Fsadni
Therapeutic Area Head Ophthalmology
Position: Therapeutic Area Head Ophthalmology at Annexin since 2022
Education and professional experience: Mario Fsadni, MBChB, MRCOphth, MSc, LLM, FMH, obtained his Medical Degree and Ophthalmology training in Manchester, UK. He brings experience gained over several years of ophthalmic drug development. He was previously the Global Medical Director at Novartis Ophthalmics and Director Product Development (Ophthalmology) at Allergan, before starting a consultancy designed specifically for the development of pharmaceutical products for ophthalmic disorders. Mario has had an active part in projects spanning all sub-therapeutic areas in ophthalmology, sixteen of which have had successful global marketing approval.
Shareholdings in the Company: No shares. 200 000 share option rights serie 2022/2025.
Alain Thibault
Therapeutic Area Head Oncology
Position: Therapeutic Area Head Oncology since 2023
Education and professional experience: Alkain Thibault obtained his Medical Degree at McGill University Montreal, Canada and Board Certification in Oncology and Internal Medicine in the US. He has held management and specialist positions at Roche, J&J and Regeneron as well as Chief Medical Officer roles in biotech companies. Alain has as a medical oncologist extensive global experience leading novel compounds through clinical development.
